Latest Headlines

  1. bioAffinity Technologies And Pictor, Inc. Partner To Develop And Commercialize Bioaffinity's Diagnostics For Asthma And COPD 7/22/2026
  2. Cancer Cell Diagnostics (CCDx) Debuts Whole-Cell Genomic Profiling To Redefine Liquid Biopsy 7/22/2026

    Cancer Cell Diagnostics today announced the commercial launch of its CellSight DNA comprehensive genomic profiling test. This test is built on a fundamentally distinct source material from conventional liquid biopsy.

  3. Cizzle Bio Launches CIZ1B Biomarker Blood Test For Early Lung Cancer 7/22/2026

    Texas-based Cizzle Bio, Inc., a biotechnology company advancing biomarker blood tests for early lung and gastric cancers, today announced the commercial launch of its proprietary CIZ1B Biomarker Blood Test for Lung Cancer for licensed health care providers in Dallas-Fort Worth and San Antonio.

  4. Cepheid To Unveil Third-Generation GeneXpert® System At ADLM 2026, Advancing Molecular Diagnostic Capabilities 7/22/2026

    Cepheid, a Danaher company, and a leader in molecular diagnostics, will unveil the third generation of the GeneXpert system at the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Scientific Meeting in a special booth presentation on Tuesday, July 28.

  5. Roche Showcases Intelligent Lab Solutions And High-Precision Instruments At ADLM 2026 To Help Laboratories Address Workforce And Workflow Challenges 7/22/2026
  6. Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies In India For Tuberculosis Test On PCR Platform 7/22/2026

    Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro® instrument.

  7. Steps Taken To Enhance National Preparedness Against Emerging Infectious Diseases 7/21/2026

    The Union Health Ministry regularly reviews and strengthens its preparedness for the detection and response to emerging infectious diseases through various national programs and institutions including the Viral Research and Diagnostic Laboratories (VRDL) network, genomic surveillance initiatives and wastewater surveillance for early detection of pathogens of public health importance. The preparedness is further strengthened through participation in simulation exercises, mock drills and rapid outbreak response mechanisms.

  8. Seek Labs Announces Publication In Nature Communications Validating ANINA™, A Room-Temperature, Instrument-Free Amplification Diagnostic Technology Designed To Deliver PCR-Level Sensitivity At The Point Of Need 7/21/2026

    Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, announced the publication of a peer-reviewed manuscript in Nature Communications describing Annexing Isothermal Nucleotide Amplification (ANINA), the proprietary amplification chemistry that powers its SeekIt molecular diagnostic platform.

  9. OraSure Receives Emergency Use Authorization For Second Generation Ebola Test 7/21/2026

    OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its second generation OraQuick™ Ebola 2.0 Rapid Antigen Test for use with whole blood in live patients, as well as cadaveric oral fluid from individuals suspected to have had Ebola disease at the time of death.

  10. SYNLAB And Microba Advance Partnership With Latest-Generation Microbiome Testing 7/20/2026

    SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences have entered into a new three-year agreement to advance their partnership in microbiome diagnostics across selected markets in Europe and Latin America.